CAI
ALLR

Capital Advisors Inc’s Allarity Therapeutics ALLR Stock Holding History

Capital Advisors Inc’s Portfolio ALLR Stock Details ALLR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,000
Closed -$108K – 361
2025
Q4 		$108K Buy
+100,000
New +$127K ﹤0.01% 333

Other funds holding ALLR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Capital Advisors Inc's ALLR Position: Q1 2026 in Review

Capital Advisors Inc sold out of Allarity Therapeutics (ALLR) in Q1 2026, closing a stake of 100,000 shares — an estimated $108K sold.

Capital Advisors Inc first reported a position in ALLR in Q4 2025 and held it in 1 quarter. The position peaked at $108K in Q4 2025. 14 funds tracked by Wall St. Rank hold ALLR as of Q1 2026.

  • Capital Advisors Inc reported no remaining Allarity Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Capital Advisors Inc sold 100,000 Allarity Therapeutics shares in Q1 2026, an estimated $108K.
  • Capital Advisors Inc first reported a position in Allarity Therapeutics in Q4 2025 and held it in 1 quarter.
  • Capital Advisors Inc's Allarity Therapeutics position peaked at $108K in Q4 2025.
  • 14 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q1 2026.

Based on Capital Advisors Inc's 13F filing for Q1 2026, filed 27 Apr 2026.